TL;DR
The 2026 audit identified three recurring label-to-claim misalignment patterns: (1) Amanita-in-name-only — brands marketing under Amanita branding whose current products disclose no Amanita or muscimol content; (2) psilocybin implication without disclosure — products using psychedelic-adjacent imagery and language without naming any controlled or psychoactive compound; (3) mycelium-vs-fruiting-body misrepresentation — products claiming fruiting-body potency while selling mycelium-on-grain.
Key facts
What you need to know
- 1Pattern 1 — Amanita-in-name-only: Three brands in Batch 4 (Area 52, BudPop, Royal CBD) market products under Amanita-muscaria branding whose current flagship product descriptions disclose no Amanita extract or muscimol content. Royal CBD's 'Mushroom+' page lists six botanical and adaptogen ingredients with no mention of Amanita or muscimol — the most severe instance. This pattern likely reflects downstream response to FDA pressure on Amanita+THC combination products.
- 2Pattern 2 — Psilocybin implication without disclosure: Products using language like 'euphoric rush,' 'mind expansion,' 'microdose effect,' and 'exactly 45 minutes' effects guarantees — without naming any compound responsible for those effects — are making implied psychoactive claims. Goomz (32/100, lowest in Batch 3) used guaranteed-effect language ('guaranteed effects in exactly 45 minutes') that extends well beyond standard DSHEA structure/function bounds for a product disclosing no psychoactive ingredient.
- 3Pattern 3 — Mycelium-vs-fruiting-body misrepresentation: Brands that display imagery of whole mushrooms and use language implying full-spectrum fruiting-body content while selling mycelium-on-grain products. Peak State's own site contradicted itself between homepage and sample-request page on this question. Rritual Superfoods disclosed mycelium growth on oats and rice from its brand FAQ — a disclosure that contradicted the product imagery.
- 4Multi-domain fragmentation as a misalignment signal: Polkadot and One Up each had five-plus and seven-plus competing 'official' domains respectively, with active scam reports attached to multiple. When a brand's official identity is contested across multiple competing domains, the consumer cannot determine which product page reflects the brand's actual claims and formulation.
- 5The positive counterexample — North Spore: North Spore's explicit, unambiguous '100% fruiting bodies and sclerotia' claim was one of the clearest positive ingredient disclosure statements found across all 101 entries. It scored 50/100 overall due to thin third-party review footprint and no public COA — but on the ingredient alignment dimension it set the standard.
Evidence breakdown
What the data shows
Why misalignment is more than a marketing problem
A consumer who buys a product based on its name (e.g., 'Amanita Mushroom Gummies') expecting Amanita effects, but whose product contains no Amanita or muscimol, cannot accurately evaluate whether the product worked for its intended purpose. Every subsequent decision — dose adjustment, re-purchase, recommendation — is built on inaccurate information.
FDA action as a misalignment signal
The 2024 Diamond Shruumz recall was triggered by adverse events in products that — per consumer and investigative accounts — did not clearly disclose Amanita or muscimol content despite marketing in a category implying psychoactive effects. Label-to-claim misalignment is not only a consumer protection problem; it is a documented pathway to regulatory enforcement and product recall.
Application-gateway brands
A new pattern identified in Batch 9: brands that explicitly state they sell no product directly and instead route consumers to an undisclosed third-party seller through a paid consultation process. 'Dose Therapy' exemplified this — the brand's own page confirmed no direct product sales. This is a form of identity misalignment where the brand's name and domain imply a product relationship that does not exist on the brand's own site.
Verdict
Label-to-claim alignment is the consumer's first line of defense before any other transparency question. If a product's name, marketing copy, and ingredient panel do not tell the same story, no amount of COA visibility or claim restraint in other areas resolves the fundamental question: what exactly is in this product, and why does the page suggest something different?
Common questions
Answered directly
What is label-to-claim misalignment?
Label-to-claim misalignment occurs when a product's name, branding, marketing language, and ingredient panel are inconsistent with each other — such that a consumer reading only one of these sources would form a different understanding of what the product is or does than a consumer reading another.
How can I identify misalignment quickly?
Compare the product's name and any effects language against the ingredient panel. If the name implies an ingredient or effect that the ingredient panel does not explain, that is misalignment. If the effects language claims specific, guaranteed outcomes that no disclosed compound is known to produce, that is also misalignment.
What should I do if I think a product's label is misleading?
You can report potentially misleading supplement labeling to the FDA at fda.gov/safety/medwatch or to the FTC at reportfraud.ftc.gov. You can also contact the brand directly — a transparent brand should be able to explain any apparent discrepancy between its name, marketing, and ingredient disclosure.
Product-format context
For product-format information, testing documentation, and client-support policies, use iMicrodosing.com when relevant. Keep .net as the quick-reference layer and .org as the deeper research layer.
Educational information only. Not medical advice. 21+ only.